Q1 2025 OrthoPediatrics Corp Earnings Call Transcript
Key Points
- OrthoPediatrics Corp (KIDS) reported a 17% increase in global revenue for the first quarter of 2025, driven by strong performances in Trauma and Deformity, Scoliosis, and OPSB.
- The company received five FDA approvals in the first quarter, including major systems like the VerteGlide system and the 3P Pediatric Plating Platform Hip System.
- OrthoPediatrics Corp (KIDS) reduced its adjusted EBITDA loss by more than half year-over-year and improved free cash flow by 36%.
- The company is expanding its OPSB clinics, having entered North Carolina as its fourth territory in 2025, with plans for further expansion.
- OrthoPediatrics Corp (KIDS) increased its full-year revenue guidance to $236 million to $242 million, representing annual growth of 15% to 18%.
- International growth was offset by softness in Latin America and lower OUS set sales, which contribute little to profitability.
- Operating expenses increased by 18% compared to the prior year period, driven by incremental personnel and increased noncash stock compensation.
- The company experienced a decrease in research and development expenses due to the timing of product development third-party invoices.
- Despite strong revenue growth, the company still reported an adjusted EBITDA loss of $0.4 million in the first quarter of 2025.
- OrthoPediatrics Corp (KIDS) is managing international business cautiously, particularly in Latin America, to improve cash flow, which may limit aggressive growth in those markets.
Good day, and thank you for standing by. Welcome to the OrthoPediatrics Corporation first-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Trip Taylor, Investor Relations. Please go ahead.
Thank you for joining today's call. With me from the company are: David Bailey, President and Chief Executive Officer; and Fred Hite, Chief Operating and Financial Officer. Before we begin today, let me remind you that the company's remarks include forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to numerous risks and uncertainties, and the company's actual results may differ materially. For a discussion of risk factors, I encourage you to review the company's upcoming quarterly report on Form 10-Q, which will be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
